Skip to main content
Journal cover image

Sphingosine kinase 2 (SK2) targeting in the treatment of multiple myeloma: preclinical and phase I studies of opaganib, an SK 2 inhibitor, in multiple myeloma

Publication ,  Conference
Kang, Y; Fan, S; Sundaramoorthy, P; Gasparetto, C; Long, G; Garrett, A; Sellars, E; Mcintyre, J; Maines, L; Ben-Yair, VK; Smith, C; Plasse, T
Published in: EUROPEAN JOURNAL OF CANCER
November 1, 2018

Duke Scholars

Published In

EUROPEAN JOURNAL OF CANCER

EISSN

1879-0852

ISSN

0959-8049

Publication Date

November 1, 2018

Volume

103

Start / End Page

E124 / E124

Location

Dublin, IRELAND

Publisher

ELSEVIER SCI LTD

Conference Name

30th EORTC-NCI-AACR Symposium

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1117 Public Health and Health Services
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kang, Y., Fan, S., Sundaramoorthy, P., Gasparetto, C., Long, G., Garrett, A., … Plasse, T. (2018). Sphingosine kinase 2 (SK2) targeting in the treatment of multiple myeloma: preclinical and phase I studies of opaganib, an SK 2 inhibitor, in multiple myeloma. In EUROPEAN JOURNAL OF CANCER (Vol. 103, pp. E124–E124). Dublin, IRELAND: ELSEVIER SCI LTD.
Kang, Y., S. Fan, P. Sundaramoorthy, C. Gasparetto, G. Long, A. Garrett, E. Sellars, et al. “Sphingosine kinase 2 (SK2) targeting in the treatment of multiple myeloma: preclinical and phase I studies of opaganib, an SK 2 inhibitor, in multiple myeloma.” In EUROPEAN JOURNAL OF CANCER, 103:E124–E124. ELSEVIER SCI LTD, 2018.
Kang Y, Fan S, Sundaramoorthy P, Gasparetto C, Long G, Garrett A, et al. Sphingosine kinase 2 (SK2) targeting in the treatment of multiple myeloma: preclinical and phase I studies of opaganib, an SK 2 inhibitor, in multiple myeloma. In: EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD; 2018. p. E124–E124.
Kang Y, Fan S, Sundaramoorthy P, Gasparetto C, Long G, Garrett A, Sellars E, Mcintyre J, Maines L, Ben-Yair VK, Smith C, Plasse T. Sphingosine kinase 2 (SK2) targeting in the treatment of multiple myeloma: preclinical and phase I studies of opaganib, an SK 2 inhibitor, in multiple myeloma. EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD; 2018. p. E124–E124.
Journal cover image

Published In

EUROPEAN JOURNAL OF CANCER

EISSN

1879-0852

ISSN

0959-8049

Publication Date

November 1, 2018

Volume

103

Start / End Page

E124 / E124

Location

Dublin, IRELAND

Publisher

ELSEVIER SCI LTD

Conference Name

30th EORTC-NCI-AACR Symposium

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1117 Public Health and Health Services
  • 1112 Oncology and Carcinogenesis